Incidence of Mortality and Its Predictors Among Adult Visceral Leishmaniasis Patients at the University of Gondar Hospital: A Retrospective Cohort Study

References

• Biologics I for international cooperation in animal. Leishmaniasis Leishmaniasis (cutaneous and visceral). Cent Food Secur Public Health. 2017;1–18.
   Google Scholar
• WHO FR. Book review: working to overcome the global impact of neglected tropical diseases. Perspect Public Health. 2012;132(4):192. doi:10.1177/1757913912449575
   Web of Science ®Google Scholar
• Marinkelle CJ. The control of leishmaniases. Bull World Health Organ. 2010;58(6):807–818. doi:10.1088/1751-8113/44/8/085201
   Web of Science ®Google Scholar
• Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):1–12. doi:10.1371/journal.pone.0035671
   Web of Science ®Google Scholar
• Mueller YK, Nackers F, Ahmed KA, et al. Burden of visceral leishmaniasis in villages of Eastern Gedaref State, Sudan: an exhaustive cross-sectional survey. PLoS Negl Trop Dis. 2012;6(11):1–6. doi:10.1371/journal.pntd.0001872
   Web of Science ®Google Scholar
• Mueller Y, Mbulamberi DB, Odermatt P, Hoffmann A, Loutan L, Chappuis F. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop Med Int Heal. 2009;14(8):910–917. doi:10.1111/j.1365-3156.2009.02305.x
   Web of Science ®Google Scholar
• Tamiru A, Tigabu B, Yifru S, Diro E, Hailu A. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia. BMC Infect Dis. 2016;16(1):1–7. doi:10.1186/s12879-016-1746-126729246
   PubMed Web of Science ®Google Scholar
• Welay GM, Alene KA, Dachew BA. Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia. Epidemiol Health. 2016;39:1–6. doi:10.4178/epih.e2017001
   Web of Science ®Google Scholar
• Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Heal. 2003;8(8):733–739. doi:10.1046/j.1365-3156.2003.01088.x
   Web of Science ®Google Scholar
• Director H promotion and D prevention DG. Guideline for diagnosis, treatment and prevention of leishmaniasis in Ethiopia. 2017;91:1–88.
   Google Scholar
• Government SF. Guidelines for diagnosis, treatment and prevention of visceral leishmaniasis in Somalia. 2012:1–82.
   Google Scholar
• Gadisa E, Tsegaw T, Abera A, et al. Eco-epidemiology of visceral leishmaniasis in Ethiopia. BMC. 2015;8(1):1–10. doi:10.1186/s13071-015-0987-y
   Web of Science ®Google Scholar
• Singh P, Kumar M. Current treatment of visceral leishmaniasis (Kala-azar): an overview. Int J Res Med Sci. 2014;2(3):810. doi:10.5455/2320-6012.ijrms20140808
   Google Scholar
• Okwor I, Uzonna J. Review article social and economic burden of human leishmaniasis. Am Soc Trop Med Hyg. 2016;94(3):489–493. doi:10.4269/ajtmh.15-0408
   PubMed Web of Science ®Google Scholar
• Collin S, Davidson R, Ritmeijer K, et al. Conflict and Kala‐Azar: determinants of adverse outcomes of Kala‐Azar among patients in Southern Sudan. Clin Infect Dis. 2004;38(5):612–619. doi:10.1086/38120314986243
   PubMed Web of Science ®Google Scholar
• Queiroz A, Cavalcanti NV. Risk factors for death in children with visceral leishmaniasis. PLoS Negl Trop Dis. 2010;4(11):1–5. doi:10.1371/journal.pntd.0000877
   Web of Science ®Google Scholar
• Gerais M, Sérgio A, De AC, Juniorii CT, Rabelloiii A. Factors of poor prognosis of visceral leishmaniasis among children under 12 years of age. A Retrospective Monocentric Study in Belo. Rev Soc Bras Med Tro. 2013;46(1):1–7. doi:10.1063/1.3482623
   Web of Science ®Google Scholar
• Costa DL, Rocha RL, de Brito Ferreira Chaves E, et al. Predicting death from kala-azar: construction, development, and validation of a score set and accompanying software. Rev Soc Bras Med Trop. 2016;49(6):728–740. doi:10.1590/0037-8682-0258-201628001220
   PubMed Web of Science ®Google Scholar
• Belo VS, Struchiner CJ, Barbosa DS, et al. Risk factors for adverse prognosis and death in American visceral leishmaniasis: a meta-analysis. PLoS Negl Trop Dis. 2014;8(7):1–9. doi:10.1371/journal.pntd.0002982
   Web of Science ®Google Scholar
• Druzian AF, Souza AS, Campos DN, et al. Risk factors for death from visceral leishmaniasis in an urban area of Brazil. PLoS Negl Trop Dis. 2015;9(8):1–11. doi:10.1371/journal.pntd.0003982
   Web of Science ®Google Scholar
• Alemayehu M, Wubshet M. Magnitude of visceral leishmaniasis and poor treatment outcome among HIV patients: meta-analysis and systematic review. HIV/AIDS - Res Palliat Care. 2016;8:75–81. doi:10.2147/HIV.S96883
   Google Scholar
• Gebreyohannes EA, Bhagvathula AS, Abegaz TM, Seid MA. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: A systematic review and meta-analysis. Infect Dis Poverty. 2018;7(1):1–9. doi:10.1186/s40249-018-0491-729335021
   PubMed Web of Science ®Google Scholar
• Assumpção Mourão MV, Toledo A, Gomes LI, Freire VV, Rabello A. Parasite load and risk factors for poor outcome among children with visceral leishmaniasis. A cohort study in Belo Horizonte, Brazil, 2010-2011. Mem Inst Oswaldo Cruz. 2014;109(2):147–153. doi:10.1590/0074-027614025724676657
   PubMed Web of Science ®Google Scholar
• de Araújo VEM, Morais MHF, Reis IA, Rabello A, Carneiro M. Early clinical manifestations associated with death from visceral leishmaniasis. PLoS Negl Trop Dis. 2012;6(2):1–10. doi:10.1371/journal.pntd.0001511
   Web of Science ®Google Scholar
• Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, van Griensven J. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia. PLoS Negl Trop Dis. 2014;8(5):14–17. doi:10.1016/j.arth.2017.02.037
   Web of Science ®Google Scholar
• Verma S, Kumar R, Katara GK, et al. Quantification of parasite load in clinical samples of leishmaniasis patients: Il-10 level correlates with parasite load in visceral leishmaniasis. PLoS One. 2010;5(4). doi:10.1371/journal.pone.0010107
   Web of Science ®Google Scholar
• Soares MRA, Ishikawa EAY, Silva JM, Zacarias DA, Costa DL, Costa CHN. Bone marrow parasite burden among patients with new world Kala-Azar is associated with disease severity. Am J Trop Med Hyg. 2014;90(4):621–626. doi:10.4269/ajtmh.13-037624615127
   PubMed Web of Science ®Google Scholar
• Das A, Karthick M, Dwivedi S, Banerjee I, Mahapatra T. Epidemiologic correlates of mortality among symptomatic visceral leishmaniasis cases: findings from situation assessment in high endemic foci in India. PLoS Negl Trop Dis. 2016;1–12. doi:10.1371/journal.pntd.0005150
   Web of Science ®Google Scholar
• Desta A, Shiferaw S, Kassa A, Shimelis T, Dires S. Leishmaniasis. 2005;1–99.
   Google Scholar
• Aderie EM, Diro E, Zachariah R, et al. Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in Northwest Ethiopia? Trans R Soc Trop Med Hyg. 2017;111(3):107–116. doi:10.1093/trstmh/trx02328633331
   PubMed Web of Science ®Google Scholar
• Abongomera C, Diro E, Vogt F, et al. The risk and predictors of visceral leishmaniasis relapse in human immunodeficiency virus-coinfected patients in Ethiopia: a retrospective cohort study. Clin Infect Dis. 2017;65(10):1703–1710. doi:10.1093/cid/cix60729020196
   PubMed Web of Science ®Google Scholar
• Croft SL, Olliaro P. Leishmaniasis chemotherapy — challenges and opportunities. Clin Microbiol Infect. 2011;17:1478–1483. doi:10.1111/j.1469-0691.2011.03630.x21933306
   PubMed Web of Science ®Google Scholar
• Ministry of Health. Diagnosis and treatment of visceral leishmaniasis (Kal-azar) in Kenya. 2017:2–77.
   Google Scholar
• Sigdel B, Bhandary S, Rijal S. Epistaxis in visceral leishmaniasis with hematological correlation. Int J Otolaryngol. 2012;2012:10–13. doi:10.1155/2012/809056
   Google Scholar
• Werneck GL, Batista MSA, Gomes JRB, Costa DL, Costa CHN. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection. 2003;31(3):174–175. doi:10.1007/s15010-003-3139-912789476
   PubMed Web of Science ®Google Scholar